Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Rating of “Moderate Buy” by Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $17.56.

A number of equities analysts have issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays upped their price target on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th.

Alphatec Stock Down 1.3 %

Shares of Alphatec stock opened at $10.74 on Monday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec has a 52-week low of $4.88 and a 52-week high of $16.20. The company’s 50 day moving average price is $10.37 and its 200-day moving average price is $8.11. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -8.39 and a beta of 1.43.

Insider Buying and Selling at Alphatec

In other news, EVP David Sponsel sold 58,283 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the sale, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total value of $80,244.00. Following the transaction, the chief executive officer now owns 5,501,715 shares of the company’s stock, valued at $66,020,580. The trade was a 0.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 222,376 shares of company stock valued at $2,557,148. 22.80% of the stock is currently owned by company insiders.

Institutional Trading of Alphatec

Institutional investors have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after buying an additional 297,850 shares during the last quarter. Barclays PLC boosted its stake in Alphatec by 362.3% during the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after purchasing an additional 133,653 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Alphatec by 299.3% in the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock worth $343,000 after purchasing an additional 48,308 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in shares of Alphatec in the third quarter worth $2,057,000. Finally, Royce & Associates LP lifted its holdings in shares of Alphatec by 15.9% during the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock valued at $6,740,000 after purchasing an additional 165,954 shares in the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.